Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Century Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Century Therapeutics, Inc.

IPSC

Century Therapeutics, Inc.

About Century Therapeutics, Inc.

Century Therapeutics is a biotech company developing off-the-shelf allogeneic cell therapies using induced pluripotent stem cells (iPSCs). Its programs include engineered natural killer (NK) and T cells for autoimmune diseases and cancer, leveraging gene editing, protein engineering, and proprietary Allo-Evasion technology. The company focuses on scalable manufacturing, strategic partnerships, and broad patient access to innovative, potentially curative immunotherapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Century Therapeutics, Inc.

1
1
Century Therapeutics, Inc. Century Therapeutics Reports Significant Financial Decline in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Century Therapeutics, Inc. Century Therapeutics Reports $109.2M Collaboration Revenue and Strategic Pipeline Update in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Century Therapeutics, Inc. Century Therapeutics Reports $34.4 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Century Therapeutics, Inc. Century Therapeutics Reports Q2 2025 Financial Results with Revenue Shift and Workforce Reduction

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Century Therapeutics, Inc. Century Therapeutics Reports $109.2 Million Collaboration Revenue and $76.6 Million Net Income

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Century Therapeutics, Inc. Century Therapeutics Reports $126.6 Million Net Loss for 2024, Collaboration Revenue Increases

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Century Therapeutics, Inc. Century Therapeutics Reports Q3 2024 Financial Results, Collaboration Revenue Growth Amid Ongoing Losses

Via official filing (AI summary) | over 1 year ago | 0 comments